Julio Martin, GSK
Efforts to develop new medicines for diseases of the developing world (DDW) have been somewhat fragmented in the past and progress has been limited, despite considerable investment. Public-private partnership (PPP) is becoming an essential model for research in neglected disease areas. However, collaboration on this scale presents unique challenges, some of which can be well managed with the right informatics tools.
GLAXOSMITHKLINE (GSK) has pioneered a model of true open partnership with... [Download the full article on the right panel]
See how the Open Lab Foundation coordinates and communicates their experimental data for neglected disease research.